UFP Technologies Inc. filings document operating results and material events for its medical-device contract development and manufacturing business. Form 8-K reports furnish quarterly and annual earnings releases, non-GAAP financial measures, Regulation FD investor presentation materials, material definitive agreements with strategic medical customers, cybersecurity incident disclosures, and executive succession and compensation arrangements.
Proxy filings cover board elections, executive compensation, equity awards, pay-versus-performance disclosure, and shareholder voting matters. These records frame the company's governance, capital and incentive structure, customer-contract disclosures, and public reporting obligations as a Nasdaq-listed operating company.
UFP Technologies is registering a planned sale of 2,349 shares of common stock through Merrill Lynch on or after August 14, 2026, listed on NASDAQ. The shares have an aggregate market value of $625,145.67, compared with 7,745,790 shares of common stock outstanding.
The sale relates to equity compensation and option activity, including shares from stock option exercises dated June 7, 2023 and June 5, 2024, and stock awards granted on May 31, 2024, June 2, 2025, and June 1, 2026.
UFPT reporting person filed a Form 144 to sell common stock. The filing lists a planned sale of 1,000 shares of UFPT common stock through Merrill Lynch, with an anticipated sale date of August 13, 2026 on NASDAQ. The seller previously received stock awards used for compensation in 2023, 2024, and 2025, and has already sold 1,200 shares of common stock in a transaction on June 12, 2026.
UFP Technologies Inc insider Joseph John Hassett, a director, filed an amended Form 4 to correct his reported holdings of Common Stock, $.01 Par Value. The amendment states that, due to an administrative error, the prior filing understated his beneficial ownership; the correct amount beneficially owned following the reported transaction was 2,602 shares.
UFP Technologies Executive Chairman Jeffrey R. Bailly reported indirect sales of 13,011 shares of Common Stock of UFP Technologies, Inc. on August 10, 2026, executed "In Trust". The transactions were open-market sales in multiple trades at weighted average prices of $315.53, $316.58, and $317.27 per share, each within specified intraday price ranges. Bailly disclaims beneficial ownership of the trust-held shares except to the extent of any pecuniary interest and is also reported as holding 171,200 shares directly.
UFP Technologies Executive Chairman Jeffrey R. Bailly reported open-market sales of an aggregate 15,695 shares of common stock on August 6–7, 2026, through indirect holdings in a trust. Reported per-share prices include $315.06 and $318.21, with some prices disclosed as weighted averages over intraday ranges. He also holds 171,200 shares directly, separate from the trust holdings for which beneficial ownership is disclaimed except for any pecuniary interest.
UFP Technologies vice president Jason Holt reported a sale of 1,100 shares of Common Stock, $.01 Par Value, on August 6, 2026, at a price of $317 per share in a sale classified as an open market or private transaction. Following this trade, Holt now directly owns 7,878 shares of UFP Technologies common stock.
UFP Technologies, Inc. reported solid growth for the quarter ended June 30, 2026. Net sales rose 15.1% to $174.0 million, driven mainly by Surfaces and Support, Cardiovascular, Infection Control, and Orthopedics sub‑markets, with organic sales growth of 12.4%. Gross margin improved to 29.3% from 28.8%, supporting operating income of $28.1 million and net income of $20.9 million, or $2.68 diluted EPS.
For the first six months of 2026, net sales increased 9.6% to $328.2 million, and net income reached $38.3 million ($4.92 diluted EPS). Cash from operations declined to $18.8 million as receivables and inventories expanded with higher volumes. Cash was $9.0 million and total debt $117.3 million under a $275 million credit facility, with a 5.0% weighted average interest rate and covenant compliance. The business remains highly concentrated, with two customers accounting for over 20% each of sales, and management notes an ongoing AJR workforce transition and a February 2026 cyber incident that has not materially impacted operations to date.
UFP Technologies (UFPT) officer Jason D Holt reported a proposed sale of 1,100 common shares, with an aggregate market value of $348,700 and an approximate sale date of August 6, 2026. The shares were acquired from the issuer as a stock award on March 3, 2025, with compensation listed as the nature of payment.
John B. Bailly, identified as an affiliate and trustee of The R. Jeffrey Bailly Irrevocable Trust of 2022, reported a proposed sale of 28,706 UFP Technologies Inc. common shares, with an approximate sale date of August 6, 2026. The reported aggregate market value is $9,200,560.00. The trust received 109,929 shares as a gift from R. Jeffrey Bailly on November 10, 2022.
UFP Technologies (UFPT) is named as the issuer in a Form 144 notice listing officer Christopher P. Litterio’s proposed sale of 1,000 common shares, with an aggregate market value of $322,000. The approximate sale date is August 6, 2026. The acquisition information lists 1,829 common shares acquired from the issuer as compensation on March 1, 2023.